Dexamethasone sodium phosphate SR 1 is under clinical development by Taiwan Liposome and currently in Phase II for Macular Edema. According to GlobalData, Phase II drugs for Macular Edema have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexamethasone sodium phosphate SR 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate SR 1 overview

Sustained release formulaton of dexamethasone sodium phosphate (TLCx-99, TLC-399, ProDex) is under development for the treatment of macular edema due to branch retinal vein occlusion or central retinal vein occlusion. It is administered through intravitreal route. The drug candidate targets the glucocorticoid receptors. The drug candidate is an injectable formulation of liposomal dexamethasone encapsulated using bioseizer technology.

Taiwan Liposome overview

Taiwan Liposome (TLC) is a clinical-stage pharmaceutical company, which develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and infectous disease. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan

For a complete picture of Dexamethasone sodium phosphate SR 1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.